Sunday, December 21, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Eutelsat Shares Face Intense Selling Pressure

Robert Sasse by Robert Sasse
December 21, 2025
in Analysis, European Markets, Space, Telecommunications
0
Eutelsat Stock
0
SHARES
12
VIEWS
Share on FacebookShare on Twitter

Eutelsat shares concluded a punishing week by falling to fresh lows on Friday, closing at €1.61. This represented a weekly decline of 23%, with the session itself seeing a 5% drop. The severe downturn persists despite significant corporate announcements, overshadowed entirely by the dilutive impact of a recent capital increase.

Capital Raise Casts a Long Shadow

The primary driver of the sell-off remains the recently completed €1.5 billion financing round. Nearly 500 million new shares were issued at a subscription price of €1.35. This discounted price level continues to act as a powerful anchor, stifling any potential for a sustained share price recovery and creating persistent overhang in the market.

Next-Generation Satellite Plans Fail to Impress

In a strategic update on Thursday, Eutelsat OneWeb outlined the roadmap for its second-generation satellite constellation. The plan involves launching 340 Gen-2 satellites by 2027, with a focus on bolstering services for enterprise and government clients. The company has again selected the Indian Space Research Organisation (ISRO) and SpaceX as launch partners.

However, this news failed to generate any positive momentum within the investment community. Market attention remains fixed on the company’s existing financial structure rather than its future operational strategy.

Analyst Outlook and Shareholder Sentiment

Analyst commentary has provided little support. BNP Paribas recently issued a “Market Performance” rating for the stock, accompanied by a price target of €2.00. While this suggests a theoretical upside of 24%, the analysts concurrently highlighted ongoing operational risks, tempering the bullish implication of the target.

Should investors sell immediately? Or is it worth buying Eutelsat?

Sentiment was further damaged in early December by the actions of a major shareholder. SoftBank’s exit, including the sale of subscription rights for approximately 26 million shares, signaled clear skepticism from a key longstanding investor.

Technical and Fundamental Crossroads

From a technical perspective, the stock is deeply oversold, with its Relative Strength Index (RSI) hovering around 22. The immediate focus is whether the €1.50 to €1.60 support zone will hold. A breach of this level in the coming holiday-shortened week could see the share price test the capital increase floor of €1.35.

Fundamentally, the path to regaining investor confidence appears narrow. Eutelsat must announce substantial, concrete contracts for its Gen-2 constellation in a timely manner. Only demonstrable commercial success can potentially outweigh the market’s acute concerns over shareholder dilution. The company also continues to face the formidable sector-wide challenge posed by competitors like Starlink, which already operates thousands of active satellites.

Key Data Points:
* Friday’s Closing Price: €1.61 (-5% for the session)
* Weekly Performance: -23%
* Capital Increase Subscription Price: €1.35
* BNP Paribas Price Target: €2.00

Ad

Eutelsat Stock: Buy or Sell?! New Eutelsat Analysis from December 21 delivers the answer:

The latest Eutelsat figures speak for themselves: Urgent action needed for Eutelsat investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 21.

Eutelsat: Buy or sell? Read more here...

Tags: Eutelsat
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Lexicon Stock
Analysis

Lexicon Pharmaceuticals Approaches Critical Development Milestones

December 21, 2025
SmartRent Stock
Analysis

SmartRent Leadership Demonstrates Confidence with Significant Share Purchase

December 21, 2025
Viking Therapeutics Stock
Analysis

Analyst Forecasts Near-Triple-Digit Upside for Viking Therapeutics Stock

December 21, 2025
Next Post
SmartRent Stock

SmartRent Leadership Demonstrates Confidence with Significant Share Purchase

Lexicon Stock

Lexicon Pharmaceuticals Approaches Critical Development Milestones

Recommended

Church, Dwight Stock

Church & Dwight: A Study in Contrasts as Insiders Bet Against Market Skepticism

4 months ago
Technology Quantum computing Market Capitalization

The Importance of Innovation for Business Growth and Value Generation

2 years ago
Nio Stock

NIO’s Multi-Brand Strategy Powers Record Vehicle Deliveries

3 months ago
Walgreens Stock

Walgreens Stock Surges on Strategic Overhaul Announcement

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin ASML BioNTech Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Analyst Forecasts Near-Triple-Digit Upside for Viking Therapeutics Stock

Coeur Mining’s Meteoric Rise Fueled by Record Gold Prices and Strategic Ambitions

Speculative Surge in Beyond Meat Shares Amid Governance Concerns

Coinbase Shares Await a Catalyst Amid Crypto Stagnation

UBS Shares Reach Fresh Peak Amid Analyst Praise and Regulatory Relief

QuantumScape Stock Gains Momentum from Dual Catalysts

Trending

Lexicon Stock
Analysis

Lexicon Pharmaceuticals Approaches Critical Development Milestones

by Dieter Jaworski
December 21, 2025
0

Lexicon Pharmaceuticals finds itself at a pivotal juncture in its evolution into a research-driven biopharma entity. The...

SmartRent Stock

SmartRent Leadership Demonstrates Confidence with Significant Share Purchase

December 21, 2025
Eutelsat Stock

Eutelsat Shares Face Intense Selling Pressure

December 21, 2025
Viking Therapeutics Stock

Analyst Forecasts Near-Triple-Digit Upside for Viking Therapeutics Stock

December 21, 2025
Coeur Mining Stock

Coeur Mining’s Meteoric Rise Fueled by Record Gold Prices and Strategic Ambitions

December 21, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Lexicon Pharmaceuticals Approaches Critical Development Milestones
  • SmartRent Leadership Demonstrates Confidence with Significant Share Purchase
  • Eutelsat Shares Face Intense Selling Pressure

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com